- Founded
- 2021
- Stage
- Seed
- Invested
- 2021
- Status
- Private
Enlaza is creating a groundbreaking new class of protein therapeutics that deliver more efficacious and safer treatments for patients. Enlaza’s breakthrough War-Lock technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. We leverage our novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.